Enalapril - CAS 75847-73-3
Catalog number:
75847-73-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H28N2O5
Molecular Weight:
376.45
COA:
Inquire
Targets:
Angiotensin-converting Enzyme (ACE)
Description:
Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension, congestive heart failure, myocardial infarction, and diabetic nephropathies. Its IC50 values range from 2 to 800 nM. lt belongs to a class of medications called angiotensin converting enzyme inhibitors. pressure. lt decreases levels of angiotensin II leading to less vasoconstriction and decreased blood pressure by inhibiting ACE. lt has been shown to lower the death rate in systolic heart failure. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
White needle like crystal or crystalline powder
Synonyms:
(S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline;1-(N-((S)-1-carboxy-3-phenylpropyl)-l-alanyl)-l-proline 1'-ethyl ester;Renitec;Vasotec;L-Proline, 1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)-;Enalaprilum;Enalaprila;(S)-1-((S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)aMino)propanoyl)pyrrolidine-2-carboxylic acid
Solubility:
DMSO 99 mg/mL; Water <1 mg/Ml
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Enalapril is used in the treatment of hypertension, congestive heart failure, myocardial infarction, and diabetic nephropathies. lt decreases levels of angiotensin II leading to less vasoconstriction and decreased blood pressure by inhibiting ACE. lt lowers the death rate in systolic heart failure.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Grams to Kilograms
Boiling Point:
582.4±50.0 °C | Condition: Press: 760 Torr
Melting Point:
143-144 °C
Density:
1.204±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
GBXSMTUPTTWBMN-XIRDDKMYSA-N
InChI:
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
Canonical SMILES:
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CCCC2C(=O)O
Current Developer:
Original research factory is Valeant. It has been approved the listing.
1.Diuretics for Hypertension: A Review and Update.
Roush GC1, Sica DA2. Am J Hypertens. 2016 Apr 5. pii: hpw030. [Epub ahead of print]
This review and update focuses on the clinical features of hydrochlorothiazide (HCTZ), the thiazide-like agents chlorthalidone (CTDN) and indapamide (INDAP), potassium-sparing ENaC inhibitors and aldosterone receptor antagonists, and loop diuretics. Diuretics are the second most commonly prescribed class of antihypertensive medication, and thiazide-related diuretics have increased at a rate greater than that of antihypertensive medications as a whole. The latest hypertension guidelines have underscored the importance of diuretics for all patients, but particularly for those with salt-sensitive and resistant hypertension. HCTZ is 4.2-6.2 systolic mm Hg less potent than CTDN, angiotensin-converting enzyme inhibitors, beta blockers, and calcium channel blockers by 24-hour measurements and 5.1mm Hg systolic less potent than INDAP by office measurements. For reducing cardiovascular events (CVEs), HCTZ is less effective than enalapril and amlodipine in randomized trials, and, in network analysis of trials, it is less effective than CTDN and HCTZ-amiloride.
2.Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus.
Ali SM1, Khalifa H2, Mostafa DK3, El Sharkawy A1. Life Sci. 2016 Apr 3. pii: S0024-3205(16)30192-8. doi: 10.1016/j.lfs.2016.03.043. [Epub ahead of print]
AIM: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease, and thus, the ability of antidiabetic drugs to ameliorate renal microvascular disease may be as important as their ability to control blood glucose. Therefore, we investigated the reno-protective effect of the antidiabetic drugs, Sitagliptin and Pioglitazone, versus combined Metformin/Enalapril in a rat model of type 2 diabetes.
3.Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
McMurray JJ1, Krum H1, Abraham WT1, Dickstein K1, Køber LV1, Desai AS1, Solomon SD1, Greenlaw N1, Ali MA1, Chiang Y1, Shao Q1, Tarnesby G1, Massie BM1; ATMOSPHERE Committees Investigators. N Engl J Med. 2016 Apr 4. [Epub ahead of print]
Background Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced ejection fraction. Methods After a single-blind run-in period, we assigned patients, in a double-blind fashion, to one of three groups: 2336 patients were assigned to receive enalapril at a dose of 5 or 10 mg twice daily, 2340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combination therapy). The primary composite outcome was death from cardiovascular causes or hospitalization for heart failure. Results After a median follow-up of 36.6 months, the primary outcome occurred in 770 patients (32.
4.The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
Lainscak M1, Coats AJ2. Int J Cardiol. 2016 Mar 2;212:187-189. doi: 10.1016/j.ijcard.2016.02.130. [Epub ahead of print]
Several trials have targeted neutral endopeptidase to demonstrate benefits for patients with heart failure. In the PARADIGM-HF trial, a combination of sacubitril and valsartan was superior to enalapril in reducing the risk of death and of hospitalization for heart failure. In this editorial we apply the trial to heart failure population at large to estimate what proportion of patients might actually be treated in daily practice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Angiotensin-converting Enzyme (ACE) Products


CAS 88768-40-5 Cilazapril

Cilazapril
(CAS: 88768-40-5)

Cilazapril is a very potent and highly effective angiotensin-converting enzyme inhibitor (ACE inhibitor). It is used for the treatment of hypertension and conge...

CAS 133943-59-6 Leucylarginylproline

Leucylarginylproline
(CAS: 133943-59-6)

Leucylarginylproline, also called as H-Leu-Arg-Pro-OH, is an angiotensin-converting enzyme (ACE) inhibitor (IC50= 0.27μM).

CAS 82834-16-0 Perindopril

Perindopril
(CAS: 82834-16-0)

Perindopril is a long-acting ACE inhibitor. It is used to treat patients with hypertension, diabetes mellitus type 2, coronary heart disease, chronic heart fail...

CAS 131-01-1 Deserpidine

Deserpidine
(CAS: 131-01-1)

Deserpidine is an antihypertensive drug related to Reserpine. It is naturally found in Rauvolfia spp. Deserpidine is a competitive ACE (angiotensin converting e...

CAS 75847-73-3 Enalapril

Enalapril
(CAS: 75847-73-3)

Enalapril is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension, congestive heart failure, myocardial infarction, and diabet...

CAS 87333-19-5 Ramipril

Ramipril
(CAS: 87333-19-5)

Ramipril is a second generation angiotensin-converting enzyme (ACE) inhibitor that acts as a prodrug, which is hydrolyzed in vivo to the active metabolite ramip...

CAS 167305-00-2 Omapatrilat

Omapatrilat
(CAS: 167305-00-2)

Omapatrilat, an octahydropyridothiazepine derivative, has been found to be an ACE inhibitor as well as an endopeptidase inhibitor and was once studied in heart ...

CAS 83915-83-7 Lisinopril

Lisinopril
(CAS: 83915-83-7)

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor with a number of properties distinguish it from other ACE inhibitors: It is hydrophilic, has a lo...

CAS 103733-49-9 Quinapril Diketopiperazine

Quinapril Diketopiperazine
(CAS: 103733-49-9)

Quinapril Diketopiperazine is a derivative and a metabolite of Quinapril that acts as an angiotensin-converting enzyme(ACE) inhibitor. It prevents the conversio...

CAS 107133-36-8 Perindopril Erbumine

Perindopril Erbumine
(CAS: 107133-36-8)

Perindopril Erbumine displays a higher binding affinity for the bradykinin binding sites than the angiotensin I binding sites of the angiotensin-converting enzy...

CAS 109715-88-0 Moexipril

Moexipril
(CAS: 109715-88-0)

Moexipril is a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor. It has antihypertensive activity. lt is hydrolyzed into its active form moexiprilat...

Indolapril hydrochloride
(CAS: 80828-32-6)

Indolapril hydrochloride is a nonsulfhydryl ACE (angiotensin converting enzyme) inhibitor. It is an antihypertensive agent.

CAS 87679-37-6 Trandolapril

Trandolapril
(CAS: 87679-37-6)

Trandolapril is an angiotensin converting enzyme (ACE) inhibitor. It has a longer biological half-life and a high degree of lipophilicity than others. It is use...

CAS 103775-10-6 Moexipril

Moexipril
(CAS: 103775-10-6)

Moexipril is a potent orally active nonsulfhydryl angiotensin converting enzyme(ACE) inhibitor with antihypertensive activity. It is used for the treatment of h...

CAS 84680-54-6 Enalaprilat Dihydrate

Enalaprilat Dihydrate
(CAS: 84680-54-6)

Enalaprilat is the active metabolite of enalapril. It is the first dicarboxylate-containing ACE inhibitor.

Enalaprilat D5 Sodium Salt
(CAS: 1356922-29-6)

The isotope labelled form of Enalaprilat Sodium Salt, an ACE inhibitor, is a hydrolysate of Enalapril which could be an effective antihypertensive agent.

CAS 62571-86-2 Captopril

Captopril
(CAS: 62571-86-2)

Captopril is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure.

PD-113413
(CAS: 103733-50-2)

PD-113413 is a metabolite of quinapril, which is an angiotensin-converting enzyme(ACE) inhibitor. It is used in the treatment of hypertension and congestive hea...

CAS 152685-85-3 Hemorphin-7

Hemorphin-7
(CAS: 152685-85-3)

Hemorphin-7, a hemorphin peptide with antinociceptive and antihypertensive effects, is an endogenous opioid peptide derived from the β-chain of hemoglobin. Hemo...

CAS 92077-78-6 Cilazapril Monohydrate

Cilazapril Monohydrate
(CAS: 92077-78-6)

Cilazapril is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.

Chemical Structure

CAS 75847-73-3 Enalapril

Quick Inquiry

Verification code

Featured Items